Arcus Biosciences, Inc.

NYSE:RCUS

Biotechnology

Healthcare
$15.78 -0.39%

-$0.09 today

Market cap
$2.27B
Beta
0.84
P/E (TTM)
-8.2
EPS (TTM)
-$2.94
52W Low $7.91High $28.72

Volume 1.07M

Average 1.17M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$482.00M

FY 2025 · Annual

Investing Cash Flow

$66.00M

FY 2025 · Annual

Financing Cash Flow

$488.00M

FY 2025 · Annual

+76.2% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income52.83M(267M)(307M)(283M)(353M)
Depreciation & Amortization4M6M8M10M10M
Deferred Income Tax00000
Stock-Based Compensation55M65M73M76M60M
Change in Working Capital(375.62M)623M(71M)22M(194M)
Accounts Receivables(17.05M)704M15M28M9M
Inventory00000
Accounts Payables(4.77M)8M(1M)3M24M
Other Working Capital(353.8M)(89M)(85M)(9M)(227M)
Other Non-Cash Items7.62M11M(9M)5M(5M)
Operating Cash Flow(256.17M)438M(306M)(170M)(482M)
Capital Expenditures(26.08M)(6M)(24M)(6M)(2M)
Acquisitions (Net)00000
Purchases of Investments(718.87M)(1.24B)(788M)(1.04B)(1.08B)
Sales of Investments741.08M837M1.01B965M1.14B
Other Investing Activities0(3M)000
Investing Cash Flow(3.87M)(413M)194M(84M)66M
Debt Repayment5M0047M49M
Common Stock Issued232.35M23M25M228M439M
Common Stock Repurchased(6K)0000
Dividends Paid00000
Other Financing Activities010M8M2M0
Financing Cash Flow237.34M33M33M277M488M
Effect of Forex Changes(2.8M)0000
Net Change in Cash(25.5M)58M(79M)23M72M
Free Cash Flow(282.25M)432M(330M)(176M)(484M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$353.0M
+ D&A$10.0M
+ Stock-Based Comp$60.0M
+ Deferred Tax$0
- Working Capital-$194.0M
- Other Non-Cash-$5.0M
= Operating Cash Flow-$482.0M
- Capex-$2.0M
= Free Cash Flow-$484.0M

Analysis

FY2025 free cash flow is -$484.0M. FCF conversion is 137.1% of net income. Operating cash flow was -$482.0M, with capex of -$2.0M. The largest bridge item is Working Capital at -$194.0M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 4, 2026
8-KCurrent reportNov 4, 2026
8-KCurrent reportOct 23, 2026
424B5424B5 filingOct 22, 2026
8-KCurrent reportOct 21, 2026

Does RCUS generate free cash flow?

Arcus Biosciences, Inc. (RCUS) generated -$484.00M of free cash flow in fiscal 2025.

How much operating cash flow does RCUS produce?

Operating cash flow was -$482.00M, before capital expenditures of $2.00M.